News | NewsSVB Securities Continues its Independent Operations Unimpeded by Silicon Valley Bank’s Receivership ProceedingsMarch 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Clearwater Analytics’ (NYSE: CWAN) $195 Million Follow-On OfferingMarch 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Revolution Medicines’ (Nasdaq: RVMD) $300 Million Follow-On OfferingMarch 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for 2seventy bio’s (Nasdaq: TSVT) Upsized $125 Million Follow-On OfferingMarch 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Travere Therapeutics’ (Nasdaq: TVTX) $200 Million Follow-On OfferingMarch 2023
News | Deal AnnouncementSVB Securities Serves as Exclusive Financial Advisor to Asceneuron on its Licensing Agreement with Ferrer for ASN90 for the Treatment of Progressive Supranuclear Palsy (PSP)February 2023
News | Deal AnnouncementSVB Securities Serves as Lead Placement Agent for Abivax’s (Euronext Paris: ABVX) €130 Million Private PlacementFebruary 2023
News | Deal AnnouncementSVB Securities Serves as Exclusive Financial Advisor to Accelerate Learning on Its Majority Investment by Providence Equity PartnersFebruary 2023
News | Deal AnnouncementSVB Securities Serves as Financial Advisor for Steward Health Care’s Sale of Utah Health Care SitesFebruary 2023
News | Deal AnnouncementSVB Securities Serves as Financial Advisor to OPEN Health on the Acquisition of Acsel HealthFebruary 2023
News | Deal AnnouncementSVB Securities Serves as Sole Placement Agent for Spruce Biosciences’ (Nasdaq: SPRB) $53.6 Million Private PlacementFebruary 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for CureVac’s (Nasdaq: CVAC) Upsized $250 Million Follow-On OfferingFebruary 2023